Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 15 of 15 for “"endothelial growth factor receptor-2"”.
-
Discovery of Pyrimidine-based Heterocycles as Single Agents With Combination Chemotherapy Potential And As Inhibitors Of Purine Nucleotide Biosynthesis For The Treatment of Cancer
… as well as for inhibition of one or more of the receptor tyrosine kinases (RTKs)- vascular endothelial growth factor receptor-2 (VEGFR2), platelet derived growth factor receptor-β (PDGFRβ) and epidermal growth factor receptor (EGFR) in single entities. Single agents with both antiangiogenic …
-
Dynamics of vascular normalization during anti-angiogenic therapy : implications for combination therapy
Solid tumors require blood vessels for growth, and the goal of anti-angiogenic therapy is to destroy the tumor vasculature. Recent findings suggest that anti-angiogenic therapy enhances radiation and chemotherapy responses. These findings seem paradoxical, since anti-angiogenic therapy prunes tumor …
-
Going With The Flow: Selective phosphodiesterase 4D7 (PDE4D7) regulation of vascular endothelial cell responses to fluid shear stress
Vascular endothelial cells (VECs) regulate their phenotype in response to the frictional force exerted by the flowing blood, fluid shear stress (FSS). The hemodynamics dictating this force determine, to a large extent, the likelihood that a given region of a blood vessel will develop …
-
Hypoxia Activated Prodrug and Anti-Angiogenic Therapy Cooperate to Treat Pancreatic Cancer But Elicit Immune Suppressive G-Mdsc Infiltration
… hypoxia-activated prodrug TH-302 and vascular endothelial growth factor receptor 2 (VEGFR-2) blockade. The combination of both modalities normalized tumor vasculature and led to an accumulation of DNA damage yielding a significant delay in tumor growth. In contrast to prior observations in …
-
Bioactivity and Cell-Mediated Targeting of Multistage Nanoporous Silicon Particles
… of NSP by using antibodies for vascular endothelial growth factor receptor 2 (VEGFR2) to enhance vascular targeting and relying on the natural tumor tropism of mesenchymal stem cells (MSC) to achieve dynamic targeting were investigated. Briefly, successful modulation of the release …
-
Design and Synthesis of Pyrimidine Fused Heterocycles as Single Agents with Combination Chemotherapy Potential
… angiogenic mechanisms that are vital for tumor growth and metastasis are targeted by antiangiogenic agents. Antiangiogenic agents are usually not tumoricidal but are mainly cytostatic. Combination chemotherapy with antiangiogenic and cytotoxic agents have shown significant promise and several …
-
Design and Synthesis of Pyrimidine Based Heterocycles as Potential Anti-cancer Agents with Combination Chemotherapeutic Potential or Targeted One Carbon Metabolism Inhibition and Anti-opportunistic Agents
… as well as for inhibition of one or more of the receptor tyrosine kinases (RTKs)- vascular endothelial growth factor receptor-2 (VEGFR2), epidermal growth factor receptor (EGFR) and/or platelet-derived growth factor receptor β (PDGFR- β) in single entities. Single agents with both antiangiogenic …
-
Anti-VEGF Therapy Modulates Immune Cell Infiltration and Function in Multiple Breast Cancer Models
… existing vascular network, is required for the growth of solid tumors. For this reason, tumor angiogenesis is an attractive target for tumor therapy. Many of the current anti-angiogenic therapies target vascular endothelial growth factor-A (VEGF). VEGF binds to and activates two primary VEGF …
-
Priming of STAT1 and STAT3 for cytokine-triggered degradation by the proteasome upon A2Aadenosine receptor (A2AAR) expression
The A2A adenosine receptor (A2AAR) functions as a key non-redundant suppressor of inflammatory responses in vivo. However, whether it regulates activation of the JAK-STAT pathway utilised by many pro-inflammatory cytokines is unknown. Using a vascular endothelial cell model system, I have …
-
Chronic Hypoxia and Cardiovascular Dysfunction in Sleep Apnea Syndrome
… Nitric Oxide (NO) production and vascular endothelial growth factor (VEGF) expression patterns that contribute to aberrancy of specific determinates of cardiovascular and cardiopulmonary function before, during, and after graded exercise. These patterns may further reflect pathologic …
-
Expression of Vascular Endothelial Growth Factor-A and its Receptors in Uteroplacental Tissues of the Normotensive and Hypertensive Pregnant Rat
… leading to preeclampsia and fetal intrauterine growth retardation. Many studies have shown that vascular endothelial growth factor A (VEGF-A) is a potent angiogenic factor, that is, it is responsible for the formation of new blood vessels from existing vessels. VEGF-A has been shown to be …
-
Design and Synthesis of Pyrimidine Based Fused Heterocyclics in the Potential Treatment of Cancer and Opportunistic Infection
… agents which inhibit one or more of the receptor tyrosine kinases (RTKs)- vascular endothelial growth factor receptor-2 (VEGFR2), platelet derived growth factor receptor-β (PDGFRβ) and epidermal growth factor receptor (EGFR), using molecular modeling studies. This work also reviews the …
-
Target Based Design and Synthesis of Fused Pyrimidines in the Potential Treatment of Cancer and Opportunistic Infection
… of microtubule polymerization and multiple receptor tyrosine kinase (RTK) for potential treatment of cancer; and (c) substrates for tumor-targeted therapy for cancer.</p> <p>PCP is a host species-specific infection. Most of the drugs, synthesized and evaluated so far, have been tested …
-
Deep forward and reverse phenotyping for genetic discovery in pulmonary arterial hypertension.
… the causative role of bone morphogenetic protein receptor type 2 (BMPR2) mutations shed new light on the pathogenesis of PAH. Since then, several genes have been discovered, which now account for around 25% of cases with the clinical diagnosis of idiopathic PAH (IPAH). Despite the ongoing efforts, …
-
Hypoxiemarker im equinen Endometrium im klinisch-pathomorphologischen Kontext
… der Antikörper gegen hypo-xia-inducible factor 1α (HIF-1α), Glucosetransporter 1 (GLUT1), vascular endothelial growth factor A (VEGF A) und vascular endothelial growth factor receptor 2 (VEGF-R2) hinsichtlich der Expression dieser Hypoxiemarker immunhistologisch untersucht. Für …